Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-L1 antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-L1 antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.

The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III

##STR00001##

wherein Q is selected from the group consisting of P(O)(OH).sub.2, P(O)(OH)(O.sup.M.sup.+), P(O)(O.sup.M.sup.+).sub.2 and P(O)(O.sup.).sub.2M.sup.2+; M.sup.+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M.sup.2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

The description provides compositions and methods of using a pyrophosphate analog, in which the bridging oxygen is replaced with an imido group (PNP) to increase the rate of the reverse polymerase reaction.

Provided herein are methods for treating a patient with HIV, cancer, a viral infection, or a bacterial infection, comprising administering an effective amount of activated lymphocytic cellular compositions. Related compositions, kits, and methods for modulating the immune system using the activated lymphocytic cellular compositions are also provided.

Provided herein are methods for treating a patient with HIV, cancer, a viral infection, or a bacterial infection, comprising administering an effective amount of activated lymphocytic cellular compositions. Related compositions, kits, and methods for modulating the immune system using the activated lymphocytic cellular compositions are also provided.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.